Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

EFFECT OF EARLY PHASE ADJUVANT ARTHRITIS ON HEPATIC P450 ENZYMES AND PHARMACOKINETICS OF VERAPAMIL: AN ALTERNATIVE APPROACH TO THE USE OF AN ANIMAL MODEL OF INFLAMMATION FOR PHARMACOKINETIC STUDIES

Spencer Ling and Fakhreddin Jamali
Drug Metabolism and Disposition April 2005, 33 (4) 579-586; DOI: https://doi.org/10.1124/dmd.104.002360
Spencer Ling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fakhreddin Jamali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The objective of this study was to evaluate the suitability of the early phase of adjuvant arthritis (pre-AA) as a model of inflammation for pharmacokinetic studies. Pre-AA is associated with little or no pain and discomfort as compared with fully developed adjuvant arthritis. Pre-AA was induced in male Sprague-Dawley rats with a tail base injection of Mycobacterium butyricum. Animals were monitored for symptoms of arthritis and levels of the proinflammatory mediators, serum nitrite, C-reactive protein (CRP), and tumor necrosis factor α (TNFα). On day 6, rats were administered single i.v. (2 mg/kg) or oral (20 mg/kg) doses of racemic verapamil, and S- and R-verapamil concentrations were determined by high-performance liquid chromatography. Hepatic cytochrome P450 (P450) content and verapamil protein binding were also measured. All experiments were carried out in both pre-AA and control rats. Serum nitrite, CRP, and TNFα levels were significantly elevated in pre-AA rats while signs of pain and arthritis were absent. Pre-AA also significantly elevated plasma concentrations of S- and R-verapamil after both i.v. and oral doses, due, likely, to decreased drug clearance. This was accompanied by a significant reduction in hepatic cytochrome P450, CYP3A, and CYP1A content as well as significantly reduced verapamil free fraction in pre-AA. The early phase of AA is marked by increased proinflammatory mediators and reduced verapamil clearance, as well as decreased hepatic P450 enzymes. Hence, pre-AA is a suitable model of inflammation for pharmacokinetic studies that avoids unnecessary exposure of animals to the pain and distress of fully developed adjuvant arthritis.

Footnotes

  • This work was supported by a research grant from the Canadian Institutes of Health Research, the National Science and Engineering Research Council, and the Canadian Foundation for Innovation. S.L. was supported by an Rx&D/HRFCIHR Graduate Research Scholarship in Pharmacy.

  • This work was presented in part as an abstract at the 7th Annual Symposium of the Canadian Society for Pharmaceutical Sciences, June 9–12, 2004, Vancouver, BC, Canada.

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.104.002360.

  • ABBREVIATIONS: AA, adjuvant arthritis; pre-AA, early phase adjuvant arthritis; CRP, C-reactive protein; HPLC, high-performance liquid chromatography; AAG, α1-acid glycoprotein; HRP, horseradish peroxidase; NO, nitric oxide; AUC, area under the plasma concentration-time curve.

    • Received September 15, 2004.
    • Accepted January 14, 2005.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 33 (4)
Drug Metabolism and Disposition
Vol. 33, Issue 4
1 Apr 2005
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
EFFECT OF EARLY PHASE ADJUVANT ARTHRITIS ON HEPATIC P450 ENZYMES AND PHARMACOKINETICS OF VERAPAMIL: AN ALTERNATIVE APPROACH TO THE USE OF AN ANIMAL MODEL OF INFLAMMATION FOR PHARMACOKINETIC STUDIES
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

EFFECT OF EARLY PHASE ADJUVANT ARTHRITIS ON HEPATIC P450 ENZYMES AND PHARMACOKINETICS OF VERAPAMIL: AN ALTERNATIVE APPROACH TO THE USE OF AN ANIMAL MODEL OF INFLAMMATION FOR PHARMACOKINETIC STUDIES

Spencer Ling and Fakhreddin Jamali
Drug Metabolism and Disposition April 1, 2005, 33 (4) 579-586; DOI: https://doi.org/10.1124/dmd.104.002360

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

EFFECT OF EARLY PHASE ADJUVANT ARTHRITIS ON HEPATIC P450 ENZYMES AND PHARMACOKINETICS OF VERAPAMIL: AN ALTERNATIVE APPROACH TO THE USE OF AN ANIMAL MODEL OF INFLAMMATION FOR PHARMACOKINETIC STUDIES

Spencer Ling and Fakhreddin Jamali
Drug Metabolism and Disposition April 1, 2005, 33 (4) 579-586; DOI: https://doi.org/10.1124/dmd.104.002360
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • P450 cell lines for xenobiotic metabolite generation
  • New Dog, Cat, and Pig P450 2J Enzymes
  • Human ADME properties of abrocitinib
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics